The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Transformed SCLC: emerging science on histologic subtype switching
Small cell lung cancer (SCLC) transformation is a mechanism for acquired resistance to EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer (NSCLC). Triparna Sen, PhD, MS, BS, Memorial Sloan Kettering Cancer Center, New York, NY, outlines neuroendocrine transformation in lung cancer and it’s role in resistance. This interview took place during the virtual European Lung Cancer Congress 2022.
